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ABSTRACT
The growth of nuclear medicine in India is linked with the
developments in our Atomic Energy Programme. Self-sufficiency in
radiopharmaceuticals for both in viva  and in,  vitro use has been largely
achieved.  The availabil i ty of  instrumentat ion faci l i t ies  in over Wnuclear
medicine centres is  indicated.  The activi t ies of  the Radiat ion Medicine
Centre, a pioneer institute, in the fields of diagnosis, therapy and
training of personnel are summarised.
1. INTRODUCTION
Nuciear medicine is concerned with the use of artificially produced radioisotopes
for diagnostic, therapeutic and investigative purposes.
In 1938, the first working cyclotron at the University of California had produced
small amounts of radioactive phosphorous, iodine ‘and sodium. T%’  exploit the
characteristics of isotopes in biology and medicine, scientists used the unique properties
of radioactive decay. Since the emissions can be detected with great sensitivity and
measured with precision, very small quantities can be administered to delineate organs
or turnouts, to measure bodily functions or cellular metabolic processes.
2. RADIONUCLIDES AND RADIOPHARMACEUTICALS
Though artificially produced radionuclides have been in use in medicine since
the last 30-35 years and nuclear medicine, has progressed by lcaps and bounds ‘in
advanced countries, its development in India is linked and..  beg& with the
introduction of the Atomic Energy Programme. For an effective and viable nucleak
medicine programme, both radioisotopes tagged to suitable compounds. and
instruments should be easily available. Self-sufficiency in this area has been achieved
to a satisfactory extent in India. This achievement can be credited to the dedicated
and committed staff of the Radioisotope Division of the Bhabha Atomic Research
Centre (BARC), Bombay. Production and distribution .of radioisotopes on a
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commercial scale was undertaken by BARC in 1961. Since 1989, the Board of Radiation
and Isotope Technology (BRIT) was constituted to administer the radioisotope
production and applications programme of the Department. Over the years the
programme has expanded pari  paw with the growth of nuclear medicine in India.
About 50,000 consignments of a variety of radiopharmaceuticals were supplied by
BRIT this year to the .various  nuclear medicine departments in the country. The
regional centres set up at Bangalore and Delhi have processed 66 curies (2.44 TBq)
of ready to use 99mTc  products for supply to local nuclear medicine centres in the
country. All this indicates that nuclear medicine in India has been growing rapidly in
the last decade.
2.1 The w1I  Age
In the 196Os,  nuclear medicine was witnessing the 1311  age, and
radiopharmaceuticals labelled  with relatively long-lived radionuclides were in vogue,
for example, ‘311-Rose-Bengal, 131EHippuran, ‘311-l?luorescein,  etc., in addition to
203Hg-Neohydrin, ‘98Au-colloid,  @*PO,  and many others. Most of these were being
prepared and tested in BARC, Bombay. Some of the labelled  compounds that merited
attention at that time were ‘311-Berberine;  5, 5-bis-3-iodophenyl hydantoin; the
synthesis and labelling o f  N-4-iodobenzene-sulfonyl-W-propylurea,  a n d
2-(5hydroxy-2-iodophenyl)  ethylamine; and the synthesis of norepinephrine analogs,
etc. for testing their scintigraphic potential.
2.2 The *lk~  Era
The advent and widespread application of generator-produced, short-lived
radionuclides (mainly radiometallics) shifted the focus onto inorganics (Table 1). It
T-1. Thenarrownmgeof”-‘-hi~developedbt-hwaeandusedin
prtl&SrelmedtORMC
Radidpharmaceuticals Organ visualised Period of use
-ZnCl3 Bloodpoo l 196&-1975
l’hZn-colloid Reticuloendothelial system 1968-1975
113mZn-DTPA Kidneys/(brain) B68-1975
“hZnFe(OH)3  aggregates Lungs 196g-1975
“k”Zn-EDTMP Bone 1976
also resulted in the setting up of hospital-based radio/radionuclearpharmacies  in major
nuclear medicine departments/centres.  Once again, the preparation and formulation
of these products reverted back to the radiopharmacies. 113mInCI  “3mln-DTPA,
“3mln-colloid  and 1’3m1nFe(OH]3 aggregates soon followed using in-buse developed
technology. Prior to the standardisation of each of these products experimental
(chemical and biological) work was carried out on Swiss mice.
2.3 The -Tc Epoch
If ‘13,1fr  was short-lived, the 1’3mI..  era was even shorter with the emergence of
the wMo-99mTc  epoch. The indigenous solvent extraction-based process technology
for the preparation of Nass”‘Tc04  from neutron activated low specific activity %4o
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was available in 1971-72. It came alongwith a disclaimer in the package insert that
the onus for the use of the Nass”‘TcO,  product was solely with the user. This raised
many apprehensions in the minds of the radiopharmacists and clinicians. However,
follov+4rg  extensive animal studies, very soon the oral produce was subjected to
terminal steam sterilisation and itkas available as a parenteral.
Among the several radionuclides in use, *Tc is recognised as the most ideal. It
can be produced cheaply and in large quantities by means of generators. The generators
supplied in India are based on the solvent extraction technique which require
considerable skill and manipulation and at times may be difficult to handle in smaller
centres. A new concept of ‘hospital pharmacy’ was introduced, wherein, the %Tc
and other generator produced radionuclides had to be handled ‘in-house’ at the site
of use. Also, some centres with the expertise and knowledge built over the years were
able to prepare their own kits and radiopharmacy. Table 2 shows some of the
programmes usually undertaken at the Radiation Medicine Centre (RMC) Hospital
Pharmacy Department.
Table 2. The broad spectrom  of *Tc  radiopharmaceuticals  developed in-house and formulated and used
in patients ref?rred  to RMC-a  diary of events
Radiopharmaceuticals Organ visualised Date introduced
(a) Na99mTcO;  (oral)
(b) iVa 99mTc0;  (iv)
(c) Na g9mTcO; (improved iv)
WmTc-HEDP  (iv)
“mTc-pyrophosphate  (iv)
99mTc-phytate  (iv)
9hn Tc-sulfur@olloid  (iv)
ggmTc-pyridoxylidene  glutamate ( iv)
99”Tc-clucoheptonate  (iv)
“mTc-LIDA  (iv)
%Tc-citrate (iv)
99mTc-MAA (iv)
%“Tc-EDTMP  (iv)
99”Tc-DTPA  (iv)
*Tc-MDP (iv)
(a) 99mTc-Sb,S,  colloid (iv)
(b) WmTc-SbrS,colloid  (subcut)
99mTcDIPIDA(iv)
99mTciodotrimethida(iv)
99mTcbromotrimethida(iv)
Thyroid, (brain)
Thyroid (brain)
Thyroid (brain)
Bone
Bone
RES
RES
Hapatobiliary
Kidney
Hepatobiliary
Kidney/(brain)
Lung
B o n e
Kidney/(brain)
Bone
RES
Lymph node
Hepatobiliary
Hepatobil iary
Hepatobiliary
17August  1971
26 April 1972
17 August 1973
‘27 September 1973
1 February 1974
20 February 1974
25 April 1974
28 January 1975
20 August 1975
4 October 1975
30 October 1975
15 June 1978
26 July 1978
23 October 1978
29 October 1979
23 September 1980
9 October 1980
5 October 1983
30 July 1985
N.B. Some of the above formulations have also been used as aerosol dosage forms. iv= intravenous
3. INSTRUMENTATION
Scintigraphic imaging of the organs forms the main bulk of the investigations
done ,in a nuclear medicine department. Apart from the radiopharmaceuticals,
instrumentation is an important component of the study. Imaging of the organs in
the early 60s and 70s was performed using rectilinear scanners (both fast and slow).
Hard copies obtained were either dot scans or photoscans. For many years the
rectilinear scanners were the mainstay in the procedures carried out in the nuclear
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medicine centres in India. Even now some of them are still dependent on rectilinear
scans. Since the mid-70s  however, improvements in instrumentation have progressed
with the development of scintillation gamma cameras. The state-of-the-art machines
now have online computers with ever increasing sophistication of software packages
offered by manufacturers. Single photbn emission?omugraphic  (SPECT) cameras and
positron emission tomographic (PET) machines are the:more recent developments.
In India in 1972, there was only pne gamma camera in the country (at RMC), but
the latest data show (Table 2) that there are now 55 gamma cameras- and 11 SPECT
systems available in the 87 nuclear medicine centres in the’country. Until 5 years ago,
there were less than 20 gamma cameras and in the last five years, their number has
more than doubled. Table 3 shows the distribution of gamma cameras in the various
parts of the country. So it can be seen that the growth of nuclear medicine in India
has depended to a large extent on the.development of radiopharmaceuticals and the
availability of instrumentation. At this stage it is to be noted that the installation and
maintenance of a nuclear medicine department is expensive and, not @thin reach of
Table 3. Number of gamma cameras in India as on 25th June 1990
S.No. City No. of institutions No. of dameras
1. Bombay
2 . Delhi
3 . Calcutta
4. Madras
5 . Hyderabad
6 . Lucknow
7 . Indore
8 . Cuttack
9 . Chandigarh
10. Trivandrum
11. Ahmedabad
12. Surat
13. Bangalore
14. Hubli
15. Bhilai
16. Srinagar
17. Guahati
18. Jaipur
19. Rajkot
20: Ludhiana
Total
Camerns  on Order
Coimbatore
Manipal
Pune
Calcutta
Jamshedpur
Madras
Delhi
Total
9 14
7 9
4 4
4 6
4 4
1 4
1 I
1 1
1 1
1 I
1 1
1 1
1 1
1 1
1 1
1 2
1 1
1 2
1 1
1 1
43 5 7
1
1
1
1 1
1 1
7 7
Organ
Table 4. Routine procedures which can be carried out in a nuclear medicine department
Radiopharmaceutical Dose Rou te Conditions
(ma)
Per week
Static Scqns
Liver
Lymph node
Bone marrow
Hepatobiliary
Brain %TcO,
Lungs
99mTc-tiTPA
99mTc-phytate  aerosol
%Tc-DTPA  aerosol
%Tc-MAA  for perfusion
*Tc-GHA
See the last section
See later sections
Kidneys
Cardiac
Thyroid
Dynamic Studies
Cerebra1 blood flow (CBF)
*Tc-phytate
‘?&S-colloid
99mTcS-colloid
99mTc!3-colloid
*Tc-bulida  pipida
99mTc-MDP
*TcO, or any
99”Tc1abe11ed  RP
3
0.75
6-10
5’
20
1 5
3
3
10
10
15-20
5
1 5
1 5
5
4
i v Abscess, cirrhosis, primary carcinoma and
metastasis
S C
iv
iv
iv
Oral
iv/im
COPD
FTE
iv
iv
Primary disease and secondaries On request
Extent of bone lesion into marrow;myelofibrosis -do-
and to lo&se  site for biopsy
Obstructive jaundice, CB disease, etc 3-5
Most often in respect of secondaries, alsodone 15-18
in osteomyelitis, osteoid osteoma, AVN, etc
Carebrovascular accident, subduralhaematoma g-10
space occupying lesions, secondari&
Pre-operative  evaluation in lung surgerJI
Renal iesions
iv CJerebrovascular  a@deut, subdural w
iv
arteriovenous nW&tnatiou,  vascular sots,
carotidtumors
Hepatoma and vascular tumiors
iv
iv
iv
iv
Hemangiomaof the liver
Choledochal  cyst
SVCYIVCobstruction
Hypertension, renal artery stenosis; obstru&ve
30
4-e
Liver blood flow
Delayed blood pool
Delayed hepatobiliary
SW/NC  grams
Renograms
%Tc-phytate
%Tc-RBC, any
99”Tc-1abeHed  RP
9h”Tc-RBC
&Tc-BIDA
Any %Td-labelled RP
99mTc-DTPA
3-a
3-2
44
Organ Radiopharmaceutical Dose
(mCi)
Rou te Conditions Per week
Renograms
(with aorotorenal transit ‘31Z-hippuran
time, cortical transit time,
peaking time and T1/2  and
estimation of GFR and ERPF)
Micturating cystourethrogram -do-
Gastro esophageai gA”Tc-colloid
reflux
G&r0  intestinal -Tc-RBC
bleeding sites 09mTcS-colloid
Detection of Meckel’s - TcO.,
diverticulum
Three-phase bone scan
cardiac stuui-@s
First pass dynamics
%Tc-MDP
Any-T&P,  preferably
-Tc-DTPA
Blood pool (static) -ToRBC
Multi gated acquisition -T&BC
(MUGA)  (global and regional (rest, exercise & postnitro-
LVEF, global and regional glY=W
wail  motion stroke volume,
ejection fraction and paradox
images, peak ejection and
filling rates, phase and ampli-
tude images)
Mycocardial scintigraphy Fr.7
(LV size,  myo/pulm  ratios -7bTB1 -
permanentand transient at exercise and at rest
defects)
0.4
(‘3lSOWith
diuretic
and captopril
challenge)
-do-
0.5
1 0
5
1 0
asa
capsule PO
iv
iv
iv
20 iv Osteomyelitis, osteoid osteoma, cellulitis, etc.
25 as a bolus
1 5 iv
2 5 iv
i v
iv
uropathy, post-operative evaluation, donor
and recipient evaluation in transplants
Vesico-ureteric reflux
Symptomatic points, duodenal ulcer, asympto-
matic  patients
When suspected
-do-
Cardiac transit times, congenital cardic  shunts,
cardiac tumors, aneurysms of great vessels
Cardiac chamber size,  pericardial effusion,
aneurvsms
Left ventricuku  ejection fraction estimations
invarious clinical situations, for example, drug
monitoring, valvular  lesions, ischeamic heart
disease (IHD)
1
l-2
Screening in BID, angina, equivocal stress ECG, -do-
stree ECG +veZpt.  asymptomatic, stress EXG
-veZpt.  symptomatic, post-myocardial, infarct
evaluation, post-coronary angiography , pre- and
post-CABG, pre- and post-angioplasty, cardi&
myopathy (ischemic)
im =: intramuscular; iv = intravenous; RP = radiopharmaceutical
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many medical colleges and university departments. Many private hospitals and research
centres in large cities have taken the initiative of establishing well-equipped nuclear
medicine centres. The Jaslok Hospital in Bombay was the first of its kind in India to.
establish this facility in a private hospital, There has, of late, been a spurt of such
centres now all over the country. At present, there are 14 departments in the so-called
private sector.
Table 4 shows some of the more common procedures carried out in a nuclbar
medicine department.
Although there are several SPECT systems available in the country, its full
potential is still not realised, especially in the study of the central nervous system,
since the new radiopharmaceuticals useful in such studies are not available in India
as yet and the commercial products are prohibitively expensive and hence cannot be
used on a large scale and day-to-day basis. At present, there are no PET systems in
the country but hopefully in the near future, one or two centres in the country would
be fortunate enough to install this’instrument. Another great lacuna in our programmes
is the non-availability of monoclonal antibodies for radioimmunoscintigraphy which
has been a considerable setback in our efforts to keep pace with progress.
4. RADIOIMhqUNOASSAYS  AND Ij’V  VITRO NUCLEAR MEDICINEI
Although the word nuclear medicine often conjures images of gamma cameras,
SPECT and PET maehines and organ scanning, one of the most useful and widespread
applications in the use of radioisotopes is the technique of radioimmunoassays (RI&).
Since the early reports of development of RIAs  in USA, India has been a keen and
ardent advocate of this aspect of nuclear medicine. Since 1968,  RIA procedures were
developed at RMC. For many years, the use of the technique was limited to a few
centres in the country who had the expertise and need to develop the assays in their
laboratories. However, in the late’ 1970s and early 198Os,  the Radioisotope Group of
BARC had considered commercialisation  of RIA kits. Several assay kits ,are now
available, as shown in Table 5. Short training courses on RIA methods have been
conducted at BARC since the last S-10 years. The easy availability of the kits and
the training programmes ,have  given a boost to many scientists and technologists in
the country. From a single laboratory doing RIAs  in the early 197Os,  at present, there
are over 500 laboratories doing RIA using locally manufactured and imported kits.
It has in fact-become a ‘get rich quick’ enterprise.
4.1 Biomedical Research
Radionuclides as tracers play an important role in various aspects of biomedical
research. As these research projects are often individualistic and special to each
laboratory, any efforts to enumerate or describe such applications would often be futile.
4.2 Tracer Kinetics,
Thyroid uptake studies form one of the most important applications of tracer
kinetics using Na .1311  The first thyroid uptake measurements were done in 1960 by
Dr.RSSatosker  at the KEM Hospital, Bombay. Later the standardisation and uptake
measurements were established at RMC. Even today almost all the 87 centres in the
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Table 5. In vitro products and kits +
Description Code
Angiotensin I kit
Angiotensin I standard
Antiangiotensin I serum
Anti HCG serum
Anti HPL serum
Anti insulin serum
Anti Ts  serum
Anti-Thyroxine serum
Digoxin kit
HCG kit
HCG standard
HPL kit
.  .
.  .
.  .
.
. .
. .
.  .
.  .
. .
.  .
.  .
HPL standard .  .
Iodinated (I 125) HCG solution .  .
Iodinated (I 125) HPL solution .  .
Iodinated (I 125) insulin solution .
Insulin kit .  .
Insulin standard .  .
L-Thyroxine T4  standard .  .
Radioassay kit for vitamin B,, .  .
Triiodothyronine Ts  kit .  .
Triiodothyronine T3  standard .  .
Thyroxine T4  kit .  .
.  . RIAK 6
.  . RIS 5
.  . RAS  5
.  . RAS 6
.  . RAS  2
.  . RAS  1
.  . RAS  3
.  . RAS  4
.  . RIAK 8
.  . RIAK I
.  . RIS 6
1 . RIAK 2,
RIAK 2A
.  . RIS 2
.  . IOM  56
.  . IOM 55
.  . IOM 20
.  . RIAK 1,
RIAK IA
.  . RIS 1
.  . RI.3 4
.  . RAK 1
.  . RIAK 4,
RIAK 4A
.  . RIS 3
.  . RIAK 5
RIAK SA
country have a thyroid uptake system and this forms the major work of the
departmeuts. A variety of other tracer kinetics for compartmental analysis, and
biochemical studies are done at centres with specific projects pertaining to such studies.
5. THERAPEUTIC APPLICATIONS
Unfortunately therapy in nuclear medicine has a very limited and selective role
to play. The two isotopes commonly used for therapy are i3r1as  Nar3ilin  the treatment
of thyrotoxicosis and thyroid cancer and 32PNs orthophosphate for the treatment of
polycythaemia Vera. As early as 1958 Dr Mazumdar had pioneered the use of
radioiodine for thyroid diseases and cardiac diseases in India. RMC was the only
centre offering all these modalities of therapy for several years. Although 1311  for
treatment of thyrotoxicosis has been instituted in many centres all over the country,
at present only three centres in India offer 131.Z therapy for thyroid cancer and perhaps
3 or 4 centres use 32P for treatment of polycythaemia Vera. Figures 1 and 2 show the
use of radionuclides for therapy at RMC over the past 25 years.
6. TRAINING PROGRAMMES
/
Since its inception in 1963, Radiation Medicine Centre has laid considerable
emphasis on the training aspects of nuclear medicine. As a pioneer institute, it has
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been our endavour to impart knowledge of nuclear medicine to medical and
paramedical personnel so as to enable them to practice nuclear medicine in their
respective Institutes.
The prime objective of a training programme in a nuclear medicine is to make
the trainees proficient in medical radioisotopic techniques. Adequate knowledge of
the elements of nuclear physics, instrumentation, mathematics, statistics, radiation
biology, radiation protection, biochemistry, anatomy and physiology are essential for
a safe and effective practice of nuclear medicine.
6.1 Short-TermTraining Course (1965-1977)
The first introductory course of five weeks duration on medical use of
radioisotopes, was held in 1965. The course was conducted annually until1 1977. A
total of 162 (130 medical and 32 paramedical) personnel’were trained over the period
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of 12 years. The participants came from 18 states within the country and one each
from Burma and the Philippines. In a recent review, it was observed that only 47 per
cent (i.e., 76 out of 162) of the total number of trainees who attended the short course
are actively involved in practicing nuclear medicine. The purpose of the training was
to acquaint the clinicians in the country with the scope and the utility of nuclear
medicine.
With the advent of 99mTc  and gamma cameras; and with the associated
phenomenal increase in the number of radioisotopic investigations, it became apparent
that the five week introductory courses were totally inadequate.
Bombay University introduced a one year diploma course-Diploma in Radiation
Medicine (DRM)-for doctors and a one year diploma course-Diploma in Medical
Radioisotope Techniques (DMRIT)-for  science graduates in 1973.
6.2 One Year Post-Graduate Training Programme (1973-1988)
A full time formal training programme spread over one academic year was started.
at the Radiation Medicine Centre in 1973 for medica  and science graduates, Selection
of trainees for DRM’ and DMRIT courses is on all India basis and the selected students
are awarded fellowship by the Department of Atomic Energy during the course of
study. In addition, sponsored candidates from the various institutions of the country
as well as other countries are also trained.
On an average there are two lectures daily and the rest of the working hours are
devoted to the experiments, demonstrations, special clinics, scan sessions and
apprentice programme where there is a rotation through various sections of the centre.
Most lectures, demonstrations and experiments are common for DRM and
DMRIT trainees, It is only with respect to practical and apprentice training that the
programmes are different. While technologists spend more time with procedures, the
doctors spend more time with patients in the clinics. In addition, a series of lectures
are given to DMRIT students on human anatomy and physiology.
DRM/DMRIT  training programme comprises the following :
Lectures
Experiments
Demonstration .
Scan sessions (1 hour each)
Special clinics (1 hour each)
Audiovisual programmes,
including films
Apprenticeship programmes,
2 week rotation
Quiz sessions
Student’s symposia
Dissertation on a special topic.
210
30
5
‘ 30
30
13
10 areas
10
2
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During the period of 1973-1988, 95 medical personnel were tiained  for DRM
and 87 obtained their diplomas, while 82 science graduates underwent DMRIT
programme of which 74 obtained the diploma. Out of the 171 persons trained, one
medical graduate and three technologists were from other nations. In addition, five
trainees from other countries also underwent training for a period of one year without
taking the examination.
7. CONCLUSION
For the healthy growth of any discipline, a continuous endeavour to develop new
techniques and to test out old methods in more varied applications and aspects is not
only a necessity but ‘the very breath of life and survival. Lack of such outlooks would
lead to stagnation and death. The greater the competition among the Vaiious institutes
in the country, the better are the prospects for the programme of nuclear medicine
in our country. The discipline of nuclear medicine is a happy meeting ground for
physicians, physicists, biologists and chemists. With such a wide ranging interest of
multidisciplines, there can be no dearth of skill, expertise and intelligence and progress
can be rapid and far reaching.
Guest Editor’s Note on the Society of Nuclear Medicine, India
As a continuation of Dr. Samuel’s account of the growth of nuclear medicine in India, a short account
of the Society of Nuclear Medicine, India, is given in the following paragraphs.
Early in 1966, Dr. R. S. Satoskar, Head, Radioisotope Lab., KEM Hospital, Bombay, convened a
meeting  of workers in the field of nuclear medicine. It was then decided that a society should be formed
and that its membership should be qpen  to alt medical and non-medical persons who are concerned with
the use of radioisotopes for medical purposes. Consequently, the Society of Nuclear Medicine (SNM) was
formed and a formal constitution was adopted in 1967 and the Society was registered. The aims and
objectives of the Society are :
(i) To promote, encourage and help the development and advancement of nuclear medicine as a
speciality;
(ii) To encourage research work in the field;
(iii) To provide a meeting ground for scientists actively associated with the use of radioisotopes in
medical sciences; and
(iv) To take all steps to develop better understanding and to promote the application of radioisotopes
among the medical profession in India.
Dr. Vikram Sarabhai (Chairman, AEC), Shri H. N. Sethna (Director, BARC) and Dr. A. R.
Gopal-Ayengar  (Director, Biomedical Group, BARC) agreed to be patrons. Dr. K. Sundaram was the
first President and served for two terms (1969 and 1970). Brig. Mazumdar was the. second President and
also served for two terms (1971 and 1972).
The Society has a membership, at present of, about 330 (including about 20 foreign members). It
started publishing a 4-page  Newsletter in 1973. Till 1986, ten volumes (each with 4-6 issues) were brought
out with reasonable regularity. The Newsletter  ceased publication in 1986 when the Indian Journal of
Nuclear Medicine was started as an officia1 publication of SNM, largely through the initiative of Maj. Gen.
B. N. Lakshmipathi. Four issues are brought out per year.
SNM organises three memorial orations every year which are delivered at the time of the annual
meeting of the Society, in honour of Homi Bhabha, Vikram Sarabhai and Brig. Mazumdar.
The Indo-American  Society of Nuclear Medicine was formed in 1984 and works in close liaison with
SNM, India. The membership of the Indo-American  Society consists of Indians working in USA in nuclear
medicine (roughly half the-total. membership) as: we11  as Am&icah  -e%pprts  in nuclear mdioine;  A few
Indian and American menibers of the Society ~gu$arly  attend the-yptal  meetings of SEfN,  India, and
this interaction has been very valuable. I.
